1
|
Guyénard L, Tauber M, Debord-Peguet S, Berard F, Nosbaum A, Hacard F, Castells M, Nicolas JF. Case Report: Mast cell anergy: absence of symptoms after accidental re-exposure to amoxicillin/clavulanic acid 3 days after anaphylaxis. Front Allergy 2024; 5:1366922. [PMID: 38529125 PMCID: PMC10961332 DOI: 10.3389/falgy.2024.1366922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2024] [Accepted: 02/22/2024] [Indexed: 03/27/2024] Open
Abstract
Empty mast cell syndrome, also named post anaphylaxis mast cell anergy (PAMA), is a temporary state of loss of mast cell responsiveness after a severe immediate hypersensitivity reaction. In this study, we describe a case of PAMA after accidental re-exposure to amoxicillin in a patient who developed severe anaphylaxis to this drug three days earlier in the operating room. To our knowledge, this report is the second to document this phenomenon.
Collapse
Affiliation(s)
- Loris Guyénard
- Allergologie et Immunologie Clinique, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France
- TeamEpidermal Immunity and Allergy, Centre International de Recherche en Infectiologie (CIRI)—Université Claude Bernard Lyon 1—Inserm U1111—CNRS—ENS, Lyon, France
| | - Marie Tauber
- Allergologie et Immunologie Clinique, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France
- TeamEpidermal Immunity and Allergy, Centre International de Recherche en Infectiologie (CIRI)—Université Claude Bernard Lyon 1—Inserm U1111—CNRS—ENS, Lyon, France
| | - Sophie Debord-Peguet
- TeamEpidermal Immunity and Allergy, Centre International de Recherche en Infectiologie (CIRI)—Université Claude Bernard Lyon 1—Inserm U1111—CNRS—ENS, Lyon, France
- Service d’Anesthésie-Réanimation Civilo-Militaire, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
| | - Frédéric Berard
- Allergologie et Immunologie Clinique, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France
- TeamEpidermal Immunity and Allergy, Centre International de Recherche en Infectiologie (CIRI)—Université Claude Bernard Lyon 1—Inserm U1111—CNRS—ENS, Lyon, France
| | - Audrey Nosbaum
- Allergologie et Immunologie Clinique, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France
- TeamEpidermal Immunity and Allergy, Centre International de Recherche en Infectiologie (CIRI)—Université Claude Bernard Lyon 1—Inserm U1111—CNRS—ENS, Lyon, France
| | - Florence Hacard
- Allergologie et Immunologie Clinique, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France
- TeamEpidermal Immunity and Allergy, Centre International de Recherche en Infectiologie (CIRI)—Université Claude Bernard Lyon 1—Inserm U1111—CNRS—ENS, Lyon, France
| | - Mariana Castells
- Drug Hypersensitivity and Desensitization Center, Mastocytosis Center, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, United States
| | - Jean-François Nicolas
- Allergologie et Immunologie Clinique, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France
- TeamEpidermal Immunity and Allergy, Centre International de Recherche en Infectiologie (CIRI)—Université Claude Bernard Lyon 1—Inserm U1111—CNRS—ENS, Lyon, France
| |
Collapse
|
2
|
Kalmi G, Nguyen Y, Amarger S, Aubineau M, Bibes B, Blanchard-Delaunay C, Boccon-Gibod I, Bouillet L, Coppo P, Dalmas MC, Debord-Peguet S, Defendi F, Demoreuil C, Du-Thanh A, Gayet S, Hadjadj J, Jeandel PY, Launay D, Ly KH, Avoy CM, Niault M, Ollivier Y, Pelletier F, Porneuf M, Roos-Weil D, Fain O, Gobert D. Efficacy and Safety of Rituximab-Based Treatments in Angioedema With Acquired C1-Inhibitor Deficiency. J Allergy Clin Immunol Pract 2024; 12:212-222. [PMID: 37844846 DOI: 10.1016/j.jaip.2023.10.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Revised: 09/28/2023] [Accepted: 10/10/2023] [Indexed: 10/18/2023]
Abstract
BACKGROUND Angioedema (AE) due to acquired C1-inhibitor (C1-INH) deficiency (AAE-C1-INH) is related to excessive consumption of C1-INH or to anti-C1-INH antibodies, and is frequently associated with lymphoproliferative syndromes or monoclonal gammopathies. Standard of care for prophylactic treatment in this condition is not established. Rituximab may be effective to prevent attacks, especially if the lymphoid hemopathy is controlled, but data are scarce. OBJECTIVE To evaluate efficacy of rituximab in AAE-C1-INH. METHODS A retrospective multicenter study was carried out in France, including patients with AAE-C1-INH treated with rituximab between April 2005 and July 2019. RESULTS Fifty-five patients with AAE-C1-INH were included in the study, and 23 of them had an anti-C1-INH antibody. A lymphoid malignancy was identified in 39 patients, and a monoclonal gammopathy in 9. There was no associated condition in 7 cases. Thirty patients received rituximab alone or in association with chemotherapy (n = 25). Among 51 patients with available follow-up, 34 patients were in clinical remission and 17 patients had active AE after a median follow-up of 3.9 years (interquartile range, 1.5-7.7). Three patients died. The presence of anti-C1-INH antibodies was associated with a lower probability of AE remission (hazard ratio, 0.29 [95% CI, 0.12-0.67]; P = .004). Relapse was less frequent in patients with lymphoma (risk ratio, 0.27 [95% CI, 0.09-0.80]; P = .019) and in patients treated with rituximab and chemotherapy (risk ratio, 0.31 [95% CI, 0.12-0.79]; P = .014). CONCLUSIONS Rituximab is an efficient and well-tolerated therapeutic option in AE, especially in lymphoid malignancies and in the absence of detectable anti-C1-INH antibodies.
Collapse
Affiliation(s)
- Galith Kalmi
- Internal Medicine Department, Sorbonne Université, AP-HP, Hôpital Saint Antoine, Paris, France.
| | - Yann Nguyen
- Internal Medicine Department, Nord-Université Paris Cité, AP-HP, Hôpital Beaujon, Clichy-sous-Bois, France
| | - Stephanie Amarger
- Dermatology Department, University Hospital, Clermont-Ferrand, France
| | - Magali Aubineau
- Internal Medicine Department, Hospices Civils de Lyon, Lyon, France
| | - Beatrice Bibes
- Internal Medicine Department, Saint Grégoire Hospital, Rennes, France
| | | | - Isabelle Boccon-Gibod
- Internal Medicine Department, French National Reference Center for Angioedema (CREAK), Grenoble University Hospital, Grenoble, France
| | - Laurence Bouillet
- Internal Medicine Department, French National Reference Center for Angioedema (CREAK), Grenoble University Hospital, Grenoble, France; University Grenoble Alpes, CNRS, UMR 5525, VetAgro Sup, Grenoble INP, CHU Grenoble Alpes, TIMC, Grenoble, France; Internal Medicine Department, University Hospital La Tronche, Grenoble, France
| | - Paul Coppo
- Hematology Department, Sorbonne Université, AP-HP, Hôpital Saint Antoine, Paris, France
| | | | | | - Federica Defendi
- Immunology Department, Grenoble University Hospital, Grenoble, France
| | - Claire Demoreuil
- Internal Medicine Department, La Cavale Blanche University Hospital, Brest, France
| | - Aurélie Du-Thanh
- Dermatology Department, Montpellier University Hospital, Montpellier, France
| | - Stephane Gayet
- Internal Medicine Department, La Timone University Hospital, Assistance Publique-Hôpitaux de Marseille, Marseille, France
| | - Jerôme Hadjadj
- Internal Medicine Department, Sorbonne Université, AP-HP, Hôpital Saint Antoine, Paris, France
| | | | - David Launay
- Internal and Immunological Medicine Department, Lille Hospital, U1286-INFINITE-Institute for Translational Research in Inflammation, Lille University, INSERM F-59000, Lille, France
| | - Kim Heang Ly
- Internal Medicine Department, Dupuytren University Hospital, Limoges, France
| | - Chloé Mc Avoy
- Internal Medicine Department, Sorbonne Université, AP-HP, Hôpital Saint Antoine, Paris, France
| | - Mathilde Niault
- Hematology Department, Hôpital du Scorff-Lorient, Groupe Hospitalier Bretagne Sud, Lorient, France
| | - Yann Ollivier
- Medicine Department, Cote de Nacre University Hospital, Caen, France
| | - Fabien Pelletier
- Dermatology Department, Allergology Center, Besançon University Hospital, Besançon, France
| | - Marc Porneuf
- Hematology Department, Centre Hospitalier Yves le Foll, Saint-Brieuc, France (x)Hematology Department, Sorbonne Université, AP-HP, Pitié Salpêtrière Hospital, Paris, France
| | - Damien Roos-Weil
- Hematology Department, Centre Hospitalier Yves le Foll, Saint-Brieuc, France (x)Hematology Department, Sorbonne Université, AP-HP, Pitié Salpêtrière Hospital, Paris, France
| | - Olivier Fain
- Internal Medicine Department, Sorbonne Université, AP-HP, Hôpital Saint Antoine, Paris, France
| | - Delphine Gobert
- Internal Medicine Department, Sorbonne Université, AP-HP, Hôpital Saint Antoine, Paris, France
| |
Collapse
|
3
|
Gobert D, Launay D, Boccon-Gibod I, De Moreuil C, Bourgoin-Heck M, Aubineau M, Debord-Peguet S, Jeandel P, Jaussaud R, Du-Thanh A, Armengol G, Hoarau C, Ollivier Y, Pontille F, Guez S, Villedieu M, Crave J, Fain O, Bouillet L. Efficacité et tolérance du bérotralstat dans la prévention des crises récurrentes d’angiœdème héréditaire : analyse intermédiaire de l’étude observationnelle en vie réelle « BEROLIFE ». Rev Med Interne 2022. [DOI: 10.1016/j.revmed.2022.10.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|